0001493152-19-018695.txt : 20200108 0001493152-19-018695.hdr.sgml : 20200108 20191203172927 ACCESSION NUMBER: 0001493152-19-018695 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20191203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akers Biosciences, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 CORRESP 1 filename1.htm

Akers Biosciences, Inc.

201 Grove Road

Thorofare, NJ 08086

Telephone: (856) 848-8698

December 3, 2019

VIA EDGAR

Paul Fischer

Division of Corporation Finance

U.S. Securities & Exchange Commission

100 F Street, NE

Washington, D.C. 20549-4561

	Re:	Akers Biosciences, Inc.
		Registration Statement on Form S-1
		Filed November 1, 2019, as amended
		File No. 333-234447

Dear Mr. Fischer:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 9:00 a.m. EST on Thursday, December 5, 2019, or as soon as thereafter practicable. The Company hereby represents to the U.S. Securities & Exchange Commission that the Company is not required to obtain stockholder approval to increase the number of authorized shares of common stock in order to consummate the public offering pursuant to the above mentioned Registration Statement.

	Very truly yours,

	/s/ Christopher C. Schreiber
	Christopher C. Schreiber
	Executive Chairman of the Board of Directors

cc:	Ellenoff Grossman & Schole LLP
	Haynes and Boone, LLP